SB 237376

Drug Profile

SB 237376

Latest Information Update: 05 Nov 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiarrhythmics
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 05 Nov 2002 Discontinued - Phase-II for Arrhythmias in Europe (unspecified route)
  • 01 May 2001 Phase-II clinical trials for Arrhythmias in Europe (Unknown route)
  • 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top